Online citations, reference lists, and bibliographies.

Glucocorticoid-induced Osteoporosis: Pathophysiology And Therapy

E. Canalis, G. Mazziotti, A. Giustina, J. Bilezikian
Published 2007 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Glucocorticoid-induced osteoporosis (GIO) is the most common form of secondary osteoporosis. Fractures, which are often asymptomatic, may occur in as many as 30–50% of patients receiving chronic glucocorticoid therapy. Vertebral fractures occur early after exposure to glucocorticoids, at a time when bone mineral density (BMD) declines rapidly. Fractures tend to occur at higher BMD levels than in women with postmenopausal osteoporosis. In human subjects, the early rapid decline in BMD is followed by a slower progressive decline in BMD. Glucocorticoids have direct and indirect effects on the skeleton. The primary effects are on osteoblasts and osteocytes. Glucocorticoids impair the replication, differentiation and function of osteoblasts and induce the apoptosis of mature osteoblasts and osteocytes. These effects lead to a suppression of bone formation, a central feature in the pathogenesis of GIO. Glucocorticoids also favor osteoclastogenesis and as a consequence increase bone resorption. Bisphosphonates are effective in the prevention and treatment of GIO. Anabolic therapeutic strategies are under investigation.
This paper references
10.1056/NEJM199807303390502
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
K. Saag (1998)
10.1002/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K
Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
S. Cohen (1999)
10.1111/J.1365-2796.2006.01655.X
Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update.
S. Boonen (2006)
10.1016/J.ECL.2005.01.014
Osteoporosis associated with excess glucocorticoids.
J. Shaker (2005)
10.1074/jbc.271.29.17124
Cellular Mechanisms for Human Procollagenase-3 (MMP-13) Activation
V. Knäuper (1996)
The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis.
T. van Staa (2006)
10.1210/en.140.10.4382
Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis.
L. Hofbauer (1999)
10.1056/NEJMC062506
Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.
M. Kishimoto (2006)
10.1080/00365520600664276
Skeletal morbidity in inflammatory bowel disease
R. V. van Hogezand (2006)
10.1007/s002239900705
Rationale for Treatment of Involutional Osteoporosis in Women and for Prevention and Treatment of Corticosteroid-Induced Osteoporosis with Alfacalcidol
E. Schacht (1999)
10.1002/art.1780391104
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
M. Hochberg (2001)
10.1185/030079903125003062
Is bone mineral density predictive of fracture risk reduction?
C. Cefalu (2004)
10.1530/EJE.1.02147
High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption.
A. Dovio (2006)
10.1128/MCB.16.8.4128
Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids.
Z. Wu (1996)
10.1016/S0002-9343(02)01297-4
The risk of osteoporosis in Caucasian men and women with obstructive airways disease.
D. Sin (2003)
Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas.
J. Freije (1994)
10.1016/S0171-2985(11)80541-3
The C/EBP family of transcription factors.
A. Wedel (1995)
10.1016/S8756-3282(02)00687-7
Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression.
R. Pereira (2002)
Trends in prevention of glucocorticoid-induced osteoporosis.
K. Saag (2006)
10.1210/JC.2003-032066
Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34).
E. Buxton (2004)
10.1007/S11914-006-0004-7
Clinical utility of microarchitecture measurements of trabecular bone
J. Carballido-Gamio (2006)
10.1359/JBMR.2000.15.7.1368
Bone structure in patients with low bone mineral density with or without vertebral fractures.
A. Oleksik (2000)
10.1359/JBMR.2000.15.6.1006
Efficacy and Safety of Daily Risedronate in the Treatment of Corticosteroid-Induced Osteoporosis in Men and Women: A Randomized Trial*
D. Reid (2000)
10.1016/J.JOCD.2006.01.001
Standards for performing DXA in individuals with secondary causes of osteoporosis.
A. Khan (2006)
10.1210/JC.2002-012101
Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence.
M. Rubin (2002)
10.1210/ER.2003-0031
11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.
J. Tomlinson (2004)
10.1016/j.jsbmb.2005.06.020
The Vitamin D requirement in health and disease
R. Heaney (2005)
10.7326/0003-4819-125-12-199612150-00004
Calcium and Vitamin D3 Supplementation Prevents Bone Loss in the Spine Secondary to Low-Dose Corticosteroids in Patients with Rheumatoid Arthritis
L. Buckley (1996)
10.1007/s00198-005-0026-5
Body composition and vertebral fracture risk in female patients treated with glucocorticoid
H. Kaji (2005)
10.1007/s00198-005-1923-3
High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass
K. Natsui (2005)
10.1210/endo.134.1.8275958
Regulation of parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acid by glucocorticoids and PTH in ROS 17/2.8 and OK cells.
P. Ureña (1994)
10.1359/JBMR.2001.16.6.1037
Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by proinflammatory cytokines in osteoblasts: an autocrine switch from glucocorticoid inactivation to activation.
M. Cooper (2001)
10.1359/JBMR.2000.15.4.770
Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen.
A. Shiraishi (2000)
10.1210/endo.134.1.7506203
Glucocorticoid regulation of insulin-like growth factor-binding protein expression in normal human osteoblast-like cells.
R. Okazaki (1994)
10.1007/BF02405312
Effect of cortisol on periosteal and nonperiosteal collagen and DNA synthesis in cultured rat calvariae
E. Canalis (1984)
10.1016/J.BONE.2003.11.026
Perspectives on glucocorticoid-induced osteoporosis.
E. Canalis (2004)
10.1016/J.DEVCEL.2005.02.017
Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation.
D. Glass (2005)
10.1016/J.BBRC.2005.01.117
Glucocorticoid suppresses the canonical Wnt signal in cultured human osteoblasts.
K. Ohnaka (2005)
10.1111/J.1749-6632.2002.TB04204.X
Mechanisms of glucocorticoid action in bone.
E. Canalis (2005)
10.1007/s001980070111
Short-Term Increases in Bone Turnover Markers Predict Parathyroid Hormone-Induced Spinal Bone Mineral Density Gains in Postmenopausal Women with Glucocorticoid-Induced Osteoporosis
N. Lane (2000)
a meta-regression
S Amin (2007)
10.1172/JCI6610
Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone.
R. Jilka (1999)
10.1007/s00774-005-0627-2
Low-dose parathyroid hormone and estrogen reverse alkaline phosphatase activity suppressed by dexamethasone in mouse osteoblastic cells
Mei-Fway Iu (2005)
10.1074/JBC.M406294200
Glucocorticoids Inhibit the Transcriptional Activity of LEF/TCF in Differentiating Osteoblasts in a Glycogen Synthase Kinase-3β-dependent and -independent Manner*
E. Smith (2005)
Recommendations for the prevention and treatment of glucocorticoidinduced osteoporosis : 2001 update
S Boonen (2001)
10.1002/1529-0131(200107)44:7<1496::AID-ART271>3.0.CO;2-5
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 Update: American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis
L. Buckley (2001)
10.1007/BF02405069
Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis
D. Dempster (1983)
10.1172/JCI113885
Insulin-like growth factor I mediates selective anabolic effects of parathyroid hormone in bone cultures.
E. Canalis (1989)
10.1152/ajplegacy.1971.221.3.669
Bone formation by osteocytes.
D. Baylink (1971)
10.1210/jcem.80.1.7829600
Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone.
A. Giustina (1995)
10.1210/jcem.76.2.8432782
Predominance of stimulatory effects of interleukin-1 beta on isolated human pancreatic islets.
D. Eizirik (1993)
10.1016/J.AUTREV.2004.11.011
Immunogenicity of an inflammation-associated product, tyrosine nitrated self-proteins.
H. Ohmori (2005)
10.1074/JBC.M001286200
C/EBP regulates hepatic transcription of 11beta -hydroxysteroid dehydrogenase type 1. A novel mechanism for cross-talk between the C/EBP and glucocorticoid signaling pathways.
L. Williams (2000)
10.1007/s002230001146
Effects of Risedronate Treatment on Bone Density and Vertebral Fracture in Patients on Corticosteroid Therapy
S. Wallach (2000)
The Epidemiology of Corticosteroid-Induced Osteoporosis: a
T. Staa (2002)
10.1210/EN.2006-0539
Myostatin gene deletion prevents glucocorticoid-induced muscle atrophy.
H. Gilson (2007)
10.1359/JBMR.0301242
Prevention of glucocorticoid-induced apoptosis in osteocytes and osteoblasts by calbindin-D28k.
Y. Liu (2004)
10.1242/jcs.00623
Secreted antagonists of the Wnt signalling pathway
Y. Kawano (2003)
10.1210/JC.2005-2226
Thiazolidinedione use and bone loss in older diabetic adults.
A. Schwartz (2006)
10.1016/J.BONE.2006.02.005
High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study.
A. Angeli (2006)
10.1359/JBMR.060112
Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy.
G. Mazziotti (2006)
10.1210/jcem.77.2.8345044
Pulsatile secretion of parathyroid hormone in normal young subjects: assessment by deconvolution analysis.
M. Samuels (1993)
10.1126/SCIENCE.281.5381.1312
Caspases: enemies within.
N. Thornberry (1998)
10.1097/01.rhu.0000242778.65766.22
Prevalence of Evaluation and Treatment of Glucocorticoid-Induced Osteoporosis in Men
Laura M. Cruse (2006)
10.1046/j.1365-2265.2003.01888.x
Identification of the BclI polymorphism in the glucocorticoid receptor gene: association with sensitivity to glucocorticoids in vivo and body mass index
E. van Rossum (2003)
10.1074/jbc.M501900200
Essential Role of β-Catenin in Postnatal Bone Acquisition*
S. Holmen (2005)
10.1016/J.GENE.2004.06.044
Wnt signaling in osteoblasts and bone diseases.
J. Westendorf (2004)
A Randomized Double-blind Placebo-controlled Trial
J. Smith (2004)
10.1016/j.mce.2005.11.034
The essential role of glucocorticoids for proper human osteoblast differentiation and matrix mineralization
M. Eijken (2006)
10.1359/JBMR.051103
Glucocorticoid-treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice.
N. Lane (2006)
10.1016/J.BERH.2005.06.008
Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates.
E. Romas (2005)
10.1210/EDRV.19.6.0353
Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.
A. Giustina (1998)
10.1074/jbc.M300213200
Dexamethasone Enhances Osteoclast Formation Synergistically with Transforming Growth Factor-β by Stimulating the Priming of Osteoclast Progenitors for Differentiation into Osteoclasts*
A. Takuma (2003)
10.1002/ART.11283
Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
T. V. van Staa (2003)
10.1074/jbc.271.15.9033
Cortisol Inhibits the Synthesis of Insulin-like Growth Factor-binding Protein-5 in Bone Cell Cultures by Transcriptional Mechanisms (*)
B. Gabbitas (1996)
[Biochemical markers of bone in steroid (glucocorticoid)-induced osteoporosis (GIOP)].
H. Masaki (2006)
10.1002/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W
Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial.
J. Adachi (2001)
10.1359/JBMR.2002.17.8.1512
The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression.
S. Amin (2002)
10.1210/JC.2005-0646
Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression.
H. Russcher (2005)
10.1007/s00223-005-0297-z
Impaired Cortical Bone Acquisition and Osteoblast Differentiation in Mice with Osteoblast-Targeted Disruption of Glucocorticoid Signaling
L. B. Sher (2005)
10.1172/JCI28084
Glucocorticoids suppress bone formation via the osteoclast.
Hyun-Ju Kim (2006)
10.1136/gut.29.3.378
Bone histomorphometry and structure in corticosteroid treated chronic active hepatitis.
A. Stellon (1988)
10.1210/JC.2003-031422
The ER22/23EK polymorphism in the glucocorticoid receptor gene is associated with a beneficial body composition and muscle strength in young adults.
E. V. van Rossum (2004)
10.1359/JBMR.050603
Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women.
S. Bonadonna (2005)
10.1016/S8756-3452(08)70036-7
Growth Hormone Response to Growth Hormone-Releasing Hormone Is Reduced in Adult Asthmatic Patients Receiving Long-term Inhaled Corticosteroid Treatment
S. Willsie (2006)
10.1007/S11926-004-0085-1
US and UK guidelines for glucocorticoid-induced osteoporosis: Similarities and differences
J. Compston (2004)
10.1210/ENDO.139.3.5778
Dexamethasone promotes expression of membrane-bound macrophage colony-stimulating factor in murine osteoblast-like cells.
J. Rubin (1998)
10.1210/EN.2002-220129
Transgenic mice overexpressing insulin-like growth factor binding protein-5 display transiently decreased osteoblastic function and osteopenia.
R. D. Devlin (2002)
10.1007/s00198-005-2016-z
Practice patterns in patients at risk for glucocorticoid-induced osteoporosis
A. Feldstein (2005)
10.1210/endo.136.10.7664643
Cortisol represses insulin-like growth factor II receptor transcription in skeletal cell cultures.
S. Rydziel (1995)
10.1007/BF00675619
Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content
R. Laan (1993)
Essential role of beta-catenin in postnatal bone acquisition.
S. Holmen (2005)
10.1016/J.METABOL.2006.01.009
Active acromegaly enhances spontaneous parathyroid hormone pulsatility.
G. Mazziotti (2006)
10.1002/jcb.240570314
Cortisol downregulates osteoblast alpha 1 (I) procollagen mRNA by transcriptional and posttranscriptional mechanisms.
A. Delany (1995)
10.1038/nature02040
Osteoblastic cells regulate the haematopoietic stem cell niche
L. M. Calvi (2003)
10.1359/JBMR.1997.12.11.1883
Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study.
M. Lunt (1997)
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
D. Reid (2000)
10.1210/jcem.74.6.1592874
Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy.
A. Giustina (1992)
10.1007/s00198-002-1312-0
Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis
Q. Rehman (2003)
10.1016/j.tem.2006.03.009
Glucocorticoid-induced osteoporosis: an update
G. Mazziotti (2006)
10.1530/EJE.1.01841
Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects.
S. Bonadonna (2005)
10.1007/s00198-003-1426-z
Osteoporosis after solid organ and bone marrow transplantation
A. Cohen (2003)
10.1159/000061083
Growth hormone in glucocorticoid-induced osteoporosis.
F. Manelli (2002)
10.1007/s00198-003-1548-3
Oral glucocorticoid use is associated with an increased risk of fracture
M. Steinbuch (2003)
10.1126/SCIENCE.289.5484.1504
Bone resorption by osteoclasts.
S. Teitelbaum (2000)
10.1007/s00198-004-1614-5
Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies
R. D. Nijs (2004)
10.1210/EN.2003-0990
Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength.
C. O'brien (2004)
10.1172/JCI3914
Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.
N. Lane (1998)
10.1007/s001980200084
Does a Fracture at One Site Predict Later Fractures at Other Sites? A British Cohort Study
T. van Staa (2002)
10.1210/endo-112-3-931
Effect of glucocorticoids on type I collagen synthesis, alkaline phosphatase activity, and deoxyribonucleic acid content in cultured rat calvariae.
E. Canalis (1983)
10.1007/s001980200097
An Association Between Respiratory Function and Bone Mineral Density in Women from the General Community: A Cross Sectional Study
S. Lekamwasam (2002)
10.1016/J.BONE.2006.07.012
Glucocorticoids induce the differentiation of a mesenchymal progenitor cell line, ROB-C26 into adipocytes and osteoblasts, but fail to induce terminal osteoblast differentiation.
S. Ito (2007)
10.1074/jbc.270.44.26607
Cortisol Increases Interstitial Collagenase Expression in Osteoblasts by Post-transcriptional Mechanisms (*)
A. Delany (1995)
10.1152/AJPGI.00317.2006
Prednisolone-induced Ca2+ malabsorption is caused by diminished expression of the epithelial Ca2+ channel TRPV6.
S. Huybers (2007)
10.1210/EN.2006-0459
Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density.
D. Jia (2006)
10.1359/jbmr.1997.12.4.616
Episodic secretion of parathyroid hormone in postmenopausal women: assessment by deconvolution analysis and approximate entropy.
M. Samuels (1997)
10.1016/S1568-9972(03)00056-9
Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease.
N. Franchimont (2003)
10.1097/00006254-199901000-00021
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
K. Saag (1998)
10.1002/ART.22117
Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis.
T. V. van Staa (2006)
10.1359/JBMR.2002.17.6.979
Osteoblastic 11beta-hydroxysteroid dehydrogenase type 1 activity increases with age and glucocorticoid exposure.
M. Cooper (2002)
10.1210/EN.2003-0868
CCAAT/enhancer binding protein homologous protein (DDIT3) induces osteoblastic cell differentiation.
R. Pereira (2004)



This paper is referenced by
10.1530/JOE-11-0318
5α-Reduced glucocorticoids: a story of natural selection.
Mark Nixon (2012)
10.1002/9781118704493.CH13
Hard Tissue Reconstruction
M. Smith (2013)
10.1111/j.1365-2265.2011.04174.x
Glucocorticoid replacement therapy is independently associated with reduced bone mineral density in women with hypopituitarism
O. Ragnarsson (2012)
10.1210/er.2007-0036
Growth hormone, insulin-like growth factors, and the skeleton.
A. Giustina (2008)
10.1359/jbmr.081101
Divergent effects of glucocorticoids on cortical and trabecular compartment BMD in childhood nephrotic syndrome.
R. Wetzsteon (2009)
10.1016/j.jpag.2010.10.001
Congenital adrenal hyperplasia.
Selma Feldman Witchel (2011)
10.1007/978-1-4471-2745-1_9
Diseases of Mineral Metabolism and Bone: Emerging Therapeutics for Postmenopausal Osteoporosiss
Paul Dennis Miller (2012)
10.2217/AHE.11.86
The elderly inflammatory bowel disease patient and osteoporosis
Seymour Katz (2012)
10.1210/jc.2013-3851
The impact of glucocorticoid replacement on bone mineral density in patients with hypopituitarism before and after 2 years of growth hormone replacement therapy.
Hjalmar Ragnar Agnarsson (2014)
10.1210/jc.2008-1578
Age dependence of early symptomatic vertebral fracture with high-dose glucocorticoid treatment for collagen vascular diseases.
I. Tatsuno (2009)
10.1007/s00223-014-9918-8
Bone Geometry, Volumetric Bone Mineral Density, Microarchitecture and Estimated Bone Strength in Caucasian Females with Systemic Lupus Erythematosus. A Cross-Sectional Study Using HR-pQCT
S. Hansen (2014)
10.1088/1748-6041/11/5/055011
Bioactivity of dexamethasone-releasing coatings on polymer/magnesium composites.
Fátima Bensiamar (2016)
10.1016/B978-0-12-803592-4.00078-X
4.12 – Glucocorticoid Replacement in Man
G M Russell (2017)
10.1016/j.biopha.2018.02.082
Possible mechanisms of prednisolone-induced osteoporosis in zebrafish larva.
Hanliang He (2018)
10.1007/978-3-319-26757-9_8
Management of Glucocorticoid-Induced Osteoporosis
Christian Roux (2019)
10.1530/EJE-17-0154
MANAGEMENT OF ENDOCRINE DISEASE: Risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects.
G. Mazziotti (2017)
10.1186/s13018-014-0057-8
Exploring the relationship between bone density and severity of distal radius fragility fracture in women
Alvilde Sofie Strand Dhainaut (2014)
Étude descriptive d’une population suivie en consultation présentant des valeurs discordantes de quantité osseuse et de texture osseuse
Sara Kherif-Bouhidel (2018)
10.1038/s41598-019-45591-4
Risk of osteoporosis in patients with chronic inflammatory neuropathy- a population-based cohort study
S. Kim (2019)
10.21518/2079-701x-2019-21-126-134
Glucocorticoid-induced osteoporosis: pathogenesis and prevention
I. G. Krasivina (2020)
10.1002/art.24445
Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL.
L. Hofbauer (2009)
10.1007/s00198-015-3211-1
Bone status in glucocorticoid-treated men and women
E. Leib (2015)
10.1007/s11914-011-0089-5
Sclerostin: Therapeutic Horizons Based Upon Its Actions
A. G. Costa (2012)
10.1111/cpr.12735
Therapeutic potentials and modulatory mechanisms of fatty acids in bone
Minyue Bao (2019)
10.1007/s00774-012-0413-x
Glycyrrhizic acid (GCA) as 11β-hydroxysteroid dehydrogenase inhibitor exerts protective effect against glucocorticoid-induced osteoporosis
E. Ramli (2012)
10.1517/14740330802648194
Glucocorticoids and the risk of osteoporosis
L. Caplan (2009)
10.3390/pharmaceutics9010002
Design and Biological Evaluation of Delivery Systems Containing Bisphosphonates
B. Aderibigbe (2016)
10.1038/ncpendmet0923
How effective is risedronate in preventing bone loss in patients on high-dose steroids?
A. Arabi (2008)
10.1210/jc.2008-2446
Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin imbalance.
M. Faienza (2009)
Pharmaceutical care by clinical pharmacists in patients with musculoskeletal disease
Michiel Duyvendak (2010)
10.1159/000315961
Bone Health in Disorders of Sex Differentiation
S. Bertelloni (2010)
10.1002/jbmr.281
Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study.
C. Ohlsson (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar